PharmaLogic Holdings Corp., a radiopharmaceutical CDMO, and ARTBIO, a clinical-stage radiopharmaceutical company developing a new class of alpha radioligand therapies (ARTs), entered into a manufacturing and supply agreement for ARTBIO’s lead-212 (212Pb) based radiopharmaceutical candidate, AB001, for the treatment of prostate cancer.

PharmaLogic will assist ARTBIO with radiochemistry and supply of the finished radiopharmaceutical product for future Phase I and II clinical trials of AB001 from their facility in New York, using ARTBIO’s AlphaDirect 212Pb isolation technology.

212Pb is an alpha-emitting radioisotope that has gained attention for its potential applications in therapeutic medicine, particularly in targeted alpha radioligand therapy, due to the radioisotope’s attractive short-half life and other properties. Preliminary studies of radiopharmaceuticals labeled with 212Pb have been promising, indicating that 212Pb has the potential to address unmet clinical needs.

“Through this partnership, we are able to leverage PharmaLogic’s extensive and broad expertise in manufacturing radiopharmaceuticals and diagnostics, which complement well ARTBIO’s proprietary AlphaDirect technology to isolate 212Pb and discovery of novel alpha radioligand therapies,” said Emanuele Ostuni, CEO of ARTBIO. “Our combined capabilities, along with our shared goal to improve as many lives as possible, position us well to deliver safe and effective alpha radioligand therapies to the patient bedside.”

D. Scott Holbrook, chief strategy officer, and general manager for PharmaLogic said, “Consistent with our mission to bring transformative radiopharmaceuticals to patients, we are pleased to partner with ARTBIO to manufacture and supply AB001 for future clinical trials,” said “By combining our expertise, we aim to make significant strides in the field of therapeutic radiopharmaceuticals and ultimately improve the lives of patients.”